



Suggested Formula	Prednisolone 15 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 159v2
-------------------	--	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Prednisolone Sodium Phosphate, USP	TBD					
Cherry Flavor	0.3	mL				
Glycerin, USP	2.0	mL				
Medisca Oral Mix (Flavored Suspending Vehicle)	50.0	mL				
Medisca Oral Mix (Flavored Suspending Vehicle)	q.s. to 100.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible):

Prednisolone Sodium Phosphate, Glycerin

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Prednisolone 15 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 159v2
-------------------	--	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : ____	Processing Error	Qty. to measure
Prednisolone Sodium Phosphate, USP §	TBD				
Cherry Flavor	0.3	mL			
Glycerin, USP §	2.0	mL			
Medisca Oral Mix (Flavored Suspending Vehicle)	50.0	mL			
Medisca Oral Mix (Flavored Suspending Vehicle)	q.s. to 100.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.





Suggested Formula	Prednisolone 15 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 159v2
-------------------	--	-----	-------------

Preparatory Instruction

1. Ingredient quantification:

A. Determine the potency of Prednisolone Sodium Phosphate based on the certificate of analysis:

	100%
MINUS	
Water Content (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Quantity of water free Prednisolone Sodium Phosphate, in decimal	_____
MULTIPLY BY	
Assay on anhydrous basis result (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Potency of Prednisolone Sodium Phosphate, in decimal	_____
DIVIDED BY (Salt to Base conversion)	1.344
EQUALS	
i. Potency of Prednisolone Sodium Phosphate (base equivalent), in decimal	_____



Suggested Formula	Prednisolone 15 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 159v2
-------------------	--	-----	-------------

2. **Ingredient quantification:**

- A. Determine the quantity (in g) of Prednisolone Sodium Phosphate required to make a 100 mL batch of **Prednisolone (Base)** 15 mg/5 mL Oral Liquid:

Quantity of Prednisolone (Base) required for a 100 mL Oral Liquid	0.300 g
DIVIDED BY	
Potency of Prednisolone Sodium Phosphate (base equivalent), in decimal (Step 1Ai)	_____
EQUALS	
i. Quantity of Prednisolone Sodium Phosphate needed for a 100 mL Oral Liquid	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%)	1.05 to 1.09
EQUALS	
ii. Quantity of Prednisolone Sodium Phosphate needed plus processing error adjustments	_____ g

3. **Powder-liquid preparation:**

- A. Levigate the Prednisolone Sodium Phosphate (amount determined from Step 2Aii) with the Glycerin.

End result: Homogeneous liquid-like dispersion.

4. **Medium incorporation:**

- A. In the given order, sequentially add the following ingredients to the Oral Mix (Flavored Suspending Vehicle) (50.0 mL plus processing error adjustments):

- Cherry Flavor
- Homogeneous liquid-like dispersion (Step 3A)

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

Note: Add the next ingredient, once the previous one has been completely added and dispersed.



Suggested Formula	Prednisolone 15 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 159v2
-------------------	--	-----	-------------

5.	<p><u>Filling to volume:</u></p> <p>A. Add additional Oral Mix (Flavored Suspending Vehicle) to the mixture (Step 4A) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
6.	<p><u>Product transfer:</u></p> <p>A. Transfer the final product into the specified dispensing container (see “Packaging Requirements”).</p> <p><u>Note:</u> Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.</p>

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated, as per USP.	Packaging Requirements	- Tightly closed dispensing bottle. - To be dispensed with a metered-dose measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	5	Keep out of reach of children.
	2	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	6	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	3	Shake well before use.	7	Cap tightly after use.
	4	Keep refrigerated. Do not freeze.	8	May produce psychological and/or physical dependence.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Prednisolone 15 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 159v2
-------------------	--	-----	-------------

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 239.
2.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 7th Edition</i> . American Pharmaceutical Association; 2012: 324.
3.	Prednisolone Sodium Phosphate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1541.
4.	Prednisolone (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #7841.
5.	Prednisolone. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5th Edition</i> . American Pharmaceutical Association; 2012: 402.
6.	Prednisolone Sodium Phosphate (Monograph). <i>United States Pharmacopeia XXXVII / National Formulary 32</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 4395.
7.	USP <795>. <i>United States Pharmacopeia XXXVII / National Formulary 32</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 403.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.